Epicriptine
Systematic (IUPAC) name | |
---|---|
(2R,4R,7R)-N- [(1S,2S,4R,7S)- 2-hydroxy- 7-(S)-(1-methylpropyl)- 5,8-dioxo- 4-(propan-2-yl)- 3-oxa- 6,9-diazatricyclo [7.3.0.02,6]dodecan-4-yl]- 6-methyl- 6,11-diazatetracyclo [7.6.1.02,7.012,16] hexadeca- 1(16),9,12,14-tetraene- 4-carboxamide | |
Clinical data | |
| |
| |
Oral | |
Identifiers | |
19467-62-0 | |
N04BC03 (alpha/beta) | |
PubChem | CID 3084313 |
ChemSpider | 2341400 |
UNII | 5M64643B5U |
ChEBI | CHEBI:59925 |
Synonyms | beta-Dihydroergocryptine |
Chemical data | |
Formula | C32H43N5O5 |
577.715 g/mol | |
SMILES
| |
|
Epicriptine or beta-dihydroergocryptine is a dopamine agonist of the ergoline class. It constitutes one third of the mixture known as dihydroergocryptine, the other two thirds consisting of alpha-dihydroergocryptine. The alpha differs from the beta form only in the position of a single methyl group, which is a consequence of the biosynthesis in which the proteinogenic amino acid isoleucine is replaced by leucine.[1]
References
|